Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese

Phase 1

Completed

Conditions: Obesity
Overweight

Interventions: Drug: NNC0174-0833
Drug: Placebo (NNC0174-0833)
Drug: Semaglutide

First Posted Date: 2018-07-26

Last Posted Date: 2021-11-17

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 96

Registration Number: NCT03600480

Locations: 🇺🇸
Novo Nordisk Investigational Site, Overland Park, Kansas, United States

Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Standard of care
Drug: Semaglutide

First Posted Date: 2018-07-23

Last Posted Date: 2024-07-03

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1278

Registration Number: NCT03596450

Locations: 🇺🇸
Primary Care Research, Atlanta, Georgia, United States
🇺🇸
Palm Research Center Inc-Vegas, Las Vegas, Nevada, United States
🇺🇸
SC Clinical Research, Inc., Garden Grove, California, United States

and more 118 locations

Evaluation of Safety Following Immune Tolerance Induction Treatment With Turoctocog Alfa in Patients With Haemophilia A Following Inhibitor Development in NN7170-4213 Trial

Phase 3

Terminated

Conditions: Haemophilia A

Interventions: Drug: Turoctocog alfa

First Posted Date: 2018-07-17

Last Posted Date: 2020-07-07

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1

Registration Number: NCT03588741

Locations: 🇬🇧
Novo Nordisk Investigational Site, Sheffield, United Kingdom

Awareness, Care & Treatment In Obesity Management - An International Observation

Completed

Conditions: Obesity

Interventions: Other: No treatment given

First Posted Date: 2018-07-12

Last Posted Date: 2019-05-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 17287

Registration Number: NCT03584191

Locations: 🇬🇧
Novo Nordisk Investigational Site, Gatwick, United Kingdom

Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

Phase 3

Completed

Conditions: Obesity
Overweight

Interventions: Drug: Placebo (semaglutide)
Drug: Semaglutide

First Posted Date: 2018-07-02

Last Posted Date: 2024-06-03

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 17609

Registration Number: NCT03574597

Locations: 🇺🇸
Mercy Hospital and Medical Center, Chicago, Illinois, United States
🇺🇸
Preferred Primary Care Physicians Inc., Pittsburgh, Pennsylvania, United States
🇺🇸
Angel City Research, Inc., Los Angeles, California, United States

and more 827 locations

A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese

Phase 1

Completed

Conditions: Metabolism and Nutrition Disorders
Overweight or Obesity

Interventions: Drug: NNC0165-1562
Drug: Semaglutide
Drug: Placebo (NNC0165-1562)

First Posted Date: 2018-07-02

Last Posted Date: 2021-07-02

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 37

Registration Number: NCT03574584

Locations: 🇺🇸
Novo Nordisk Investigational Site, Lincoln, Nebraska, United States

A Regulatory Post-marketing Surveillance (rPMS) Study to Evaluate the Safety and Effectiveness of Saxenda®(Liraglutide 3.0 mg) in Obese Patients and Overweight Patients With Obesity-related Comorbidities in Routine Clinical Practice in Korea.

Completed

Conditions: Obesity
Overweight

Interventions: Drug: Liraglutide

First Posted Date: 2018-06-18

Last Posted Date: 2021-07-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 758

Registration Number: NCT03560336

Locations: 🇰🇷
Novo Nordisk Investigational Site, Yangsan, Korea, Republic of

Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity

Phase 3

Completed

Conditions: Obesity
Overweight

Interventions: Drug: Semaglutide 2.4 mg
Drug: Semaglutide 1.0 mg
Drug: Placebo I (Semaglutide)
Drug: Placebo II (Semaglutide)

First Posted Date: 2018-06-12

Last Posted Date: 2021-11-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1210

Registration Number: NCT03552757

Locations: 🇬🇧
Novo Nordisk Investigational Site, Wellingborough, United Kingdom

STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

Phase 3

Completed

Conditions: Overweight or Obesity
Metabolism and Nutrition Disorder

Interventions: Drug: Placebo (semaglutide)
Drug: Semaglutide

First Posted Date: 2018-06-07

Last Posted Date: 2021-11-19

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1961

Registration Number: NCT03548935

Locations: 🇬🇧
Novo Nordisk Investigational Site, Taunton, United Kingdom

Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

Phase 3

Completed

Conditions: Metabolism and Nutrition Disorder
Obesity

Interventions: Drug: Semaglutide
Drug: Placebo

First Posted Date: 2018-06-07

Last Posted Date: 2022-01-19

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 902

Registration Number: NCT03548987

Locations: 🇺🇦
Novo Nordisk Investigational Site, Odesa, Ukraine

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy